ReviewMedGenMed : Medscape general medicine2004
Advances in diabetes for the millennium: toward a cure for diabetes.
Review in MedGenMed : Medscape general medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 14 citations in OpenAlex.
- Antibody-Mediated Inhibition of Insulin-Degrading Enzyme Improves Insulin Activity in a Diabetic Mouse Model.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What does the future hold for the person with diabetes, since current therapies, including insulin, are all symptomatic and do not address the underlying biology? This article reviews the current state-of-the-art strategies aimed at curing diabetes. The central rationale to curing diabetes revolves around replacing the function of pancreatic islets, either directly through pancreatic/islet transplantation, indirectly through artificial pancreas/beta cells, or via a rebirth of islet function by reprogramming the body to create a new and expanded islet cell mass protected from further assault by autoimmune and other processes. All of these approaches are considered in context of their current status, progress, future challenges or limitations, and long-term prospects for a cure. Although the horizon is in the distance, the advances reviewed in this study predict the future to be bright, and whereas the prospect of islet neogenesis was once considered to be heretical, it is now quite fashionable amongst the scientific community.
Indexed as
Identifiers
15647717PMC1474820W140728603What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.